New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2013
09:18 EDTAMGNAmgen reports Phase 3 DESCARTES study meets primary endpoint
Amgen announced that the Phase 3 DESCARTES, Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study, study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol at week 52. The mean percent reduction in LDL-C, or "bad" cholesterol, was consistent with the results observed in the 52-week analysis of the Phase 2 OSLER study. Evolocumab significantly reduced LDL-C, as measured by the accepted standard, preparative ultracentrifugation, from baseline at week 52 compared to placebo. LDL-C reduction at week 12 was consistent with the long-term efficacy at week 52. Safety was balanced across treatment groups. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza and back pain.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
19:05 EDTAMGNBayer, Onyx report publishing of positive Phase 3 trial results
Subscribe for More Information
13:56 EDTAMGNAmgen sell-off creates buying opportunity, says Argus
After Amgen reported weaker than expected Q1 results, Argus believes that the company's key growth drivers performed well last quarter. The firm thinks the company's growth outlook looks solid, and it keeps a Buy rating on the shares.
09:34 EDTAMGNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD NFLX TSLA VZ MU WFM AMGN
09:16 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAMGNAmgen weakness a buying opportunity, says Cowen
Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.
06:54 EDTAMGNCambridge Healthtech Institute to hold a conference
Subscribe for More Information
06:53 EDTAMGNFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 22, 2014
16:32 EDTAMGNAmgen says total product sales declined 9% sequentially in Q1
Subscribe for More Information
16:25 EDTAMGNAmgen trades lower after results, first look
Subscribe for More Information
16:06 EDTAMGNAmgen sees FY14 EPS $7.90-$8.20, consensus $8.16
Subscribe for More Information
16:05 EDTAMGNAmgen reports Q1 EPS $1.87, consensus $1.94
Subscribe for More Information
15:32 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
14:35 EDTAMGNEarnings Preview: Amgen's timeline for Evolocumab will be in focus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use